Company Celularity Inc.

Equities

CELU

US1511902041

Biotechnology & Medical Research

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per Business

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs

Market Closed - Nasdaq Other stock markets 04:30:00 2024-04-26 pm EDT			5-day change	1st Jan Change
3.02 ^USD	-1.63%		-0.33%	+22.07%

Mar. 26	Celularity Receives Healthcare Common Procedure Coding System Q Code Approval from the U.S. Centers for Medicare & Medicaid Services for Biovance 3L	CI
Mar. 20	Celularity Seeks FDA Orphan Drug Status for PDA-002 in Facioscapulohumeral Muscular Dystrophy	MT

Celularity Inc. is a clinical-stage biotechnology company. The Company is engaged in developing off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer and immune and infectious diseases. It operates through three business segments: Cell Therapy, Degenerative Disease, and BioBanking. Its therapy product candidates include T cells engineered with a chimeric antigen receptor (CAR), natural killer, cells, mesenchymal-like adherent stromal cells (MLASCs), and exosomes. These therapeutic candidates target indications across cancer, infectious and degenerative diseases. Its cell therapeutic programs include CYCART-19, CYCART-201, CYNK-001, CYNK-301, CYNK-302, APPL-001, and pEXO-001. CYCART-19 is a placental-derived CAR-T cell therapy, in development for the treatment of B-cell malignancies, initially targeting the cluster of differentiation 19. pExo-001 is developed for the treatment of osteoarthritis. APPL-001 is developed for the treatment of Crohnâs disease.

Number of employees: 225

USD in Million	2021	Weight	2022	Weight	Delta
Degenerative Disease 69.3 %	16	74.1 %	12	69.3 %	-21.19%
BioBanking 30.7 %	6	25.9 %	6	30.7 %	-0.18%

USD in Million	2021	Weight	2022	Weight	Delta
United States 100.0 %	21	100.0 %	18	100.0 %	-15.75%

Managers	Title	Age	Since
Robert Hariri Gordon CEO	Chief Executive Officer	65	15-12-31
David Beers DFI	Director of Finance/CFO	54	21-07-15
Tim Wilk CTO	Chief Tech/Sci/R&D Officer	-	-
K Fletcher CMP	Compliance Officer	-	-
Adrian Kilcoyne CTO	Chief Tech/Sci/R&D Officer	-	22-10-02
John Haines ADM	Chief Administrative Officer	66	-
Carlos Ramirez IRC	Investor Relations Contact	-	-
John Colerangle LAW	General Counsel	-	-
Beth Steinbrenner HRO	Human Resources Officer	-	17-07-31
Stephen Brigido PRN	Corporate Officer/Principal	55	21-07-15

Members of the board	Title	Age	Since
Marc Mazur BRD	Director/Board Member	64	21-07-15
Dean Kehler BRD	Director/Board Member	67	17-12-31
Peter Diamandis BRD	Director/Board Member	62	17-06-30
Robert Hariri Gordon CEO	Chief Executive Officer	65	15-12-31
Diane Parks BRD	Director/Board Member	72	22-06-02
Shiu Fei Ling BRD	Director/Board Member	67	23-08-30

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	21,782,861	10,684,777 ( 49.05 %)	0	49.05 %

Name	Equities	%	Valuation
GENTING 23.63 %	5,147,376	23.63 %	27 M $
Robert Hariri Gordon 13.11 %	2,855,889	13.11 %	15 M $
Starr International Co., Inc. 7.015 %	1,528,139	7.015 %	8 M $
BRISTOL-MYERS SQUIBB COMPANY 5.487 %	1,195,327	5.487 %	6 M $
UNITED THERAPEUTICS CORPORATION 3.658 %	796,885	3.658 %	4 M $
C.V. Starr & Co., Inc. 3.508 %	764,069	3.508 %	4 M $
SORRENTO THERAPEUTICS, INC. 2.319 %	505,043	2.319 %	3 M $
Vanguard Global Advisers LLC 1.714 %	373,320	1.714 %	2 M $
Dean Kehler 0.8930 %	194,529	0.8930 %	1 M $
Adrian Kilcoyne 0.5152 %	112,224	0.5152 %	586 932 $

Name	Equities	%	Valuation
Walleye Capital LLC -	1,117,712	-	50 297 $
Privium Fund Management BV -	1,006,916	-	45 311 $
Linden Advisors LP -	550,119	-	24 755 $
Healthcare of Ontario Pension Plan Trust Fund -	350,000	-	15 750 $
Peak6 Investments LLC -	171,363	-	7 711 $
Davidson Kempner Capital Management LP -	150,800	-	6 786 $
Context Capital Management LLC -	150,000	-	6 750 $
Shay Capital LLC -	146,834	-	6 608 $
CSS LLC -	99,482	-	4 477 $
EMFO LLC -	50,000	-	2 250 $

Celularity, Inc.

170 Park Avenue

07932, Florham Park

http://celularity.com

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
CELULARITY INC.	+22.07%	65.78M
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.73B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs